OABI Nasdaq Services-Commercial Physical & Biological Research Financials FY2021βFY2025
OmniAb, Inc. had $18.7M of revenue in fiscal 2025, down 29.3% on the year before.
Last close Β· Oct 23, 2026
$4.66
2.5%Hi! I read OmniAb, Inc.βs latest annual report (fiscal 2025). Here is what stands out:
Good So-so Weak
Are sales growing?
β29.3%
No. Sales fell 29.3% last year.
Does it make a profit?
β347.0%
No. It lost money last year.
Does profit turn into cash?
β198.3%
No. It spent more cash than it brought in.
How healthy are the accounts?
1 / 7
Weak. It passes 1 of 7 health tests.
How is the share priced?
β
No P/E: it made no profit over the last four quarters.
Rules of thumb on reported numbers. A starting point, not a recommendation.
Is it selling more, and how much does it keep?
KIRA Β· OmniAb, Inc. had $18.7M of revenue in fiscal 2025, down 29.3% on the year before. Its operating margin was β369.5%, down 87.2Β pts: of every 100 in sales, about β369 is left after running the business.
In plain words: Revenue is all the money customers paid. The margins show how many cents of each dollar of sales are left over at each step: after making the product (gross), after running the business (operating) and after everything, tax included (net).
Revenue
Revenue
Margins, % of revenue
Margins, % of revenue
KIRA Β· OmniAb, Inc. lost $64.8M in fiscal 2025.
Loss periods are shown in red.
In plain words: Net income is the profit left after every cost and tax. Earnings per share (EPS) splits that profit across every share, so it shows what one share earned.
Net income
Net income
Diluted EPS
Diluted EPS
How much cash comes in, and where does it go?
KIRA Β· Free cash flow was β$37.0M in fiscal 2025, β198.3% of revenue.
Cash from operations minus capital spending.
In plain words: Profit on paper is not the same as cash in the bank. Free cash flow is the cash left after paying to run and maintain the business: the money it can hand back to shareholders, save or invest.
Free cash flow
Free cash flow
Cash from operations vs capital spending
Cash from operations vs capital spending
In plain words: Companies hand cash back in two ways: dividends (cash paid to shareholders) and buybacks (buying back their own shares, so each remaining share owns a bigger slice).
Dividends and buybacks
Diluted shares outstanding (annual)
KIRA Β· In the last 12 months, insiders bought $0.1M and sold $0.3M of shares on the open market.
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. βPlanβ marks trades under a pre-arranged Rule 10b5-1 plan.
In plain words: Insiders are the people who run or own a big part of the company. Buying with their own money can signal confidence; selling often has personal reasons, like taxes or diversifying.
Bought, 12 months
$0.1M
1 insider
Sold, 12 months
$0.3M
3 insiders
Of sales under plans
0%
$0.0M
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Apr 7, 2026 | Charles S BerkmanChief Legal Officer | Sold | 7,157 | $1.49 | $0.0M | Form 4 |
| Apr 7, 2026 | Kurt A GustafsonExecutive VP, Finance and CFO | Sold | 6,913 | $1.49 | $0.0M | Form 4 |
| Apr 7, 2026 | Matthew W FoehrPresident and CEO, Director | Sold | 19,244 | $1.49 | $0.0M | Form 4 |
| Feb 18, 2026 | Charles S BerkmanChief Legal Officer | Sold | 9,673 | $1.71 | $0.0M | Form 4 |
| Feb 18, 2026 | Kurt A GustafsonExecutive VP, Finance and CFO | Sold | 9,301 | $1.71 | $0.0M | Form 4 |
| Feb 18, 2026 | Matthew W FoehrPresident and CEO, Director | Sold | 30,843 | $1.71 | $0.1M | Form 4 |
| Feb 17, 2026 | Charles S BerkmanChief Legal Officer | Sold | 6,990 | $1.70 | $0.0M | Form 4 |
| Feb 17, 2026 | Kurt A GustafsonExecutive VP, Finance and CFO | Sold | 6,828 | $1.70 | $0.0M | Form 4 |
| Feb 17, 2026 | Matthew W FoehrPresident and CEO, Director | Sold | 20,754 | $1.70 | $0.0M | Form 4 |
| Dec 8, 2025 | Charles S BerkmanChief Legal Officer | Sold | 8,044 | $1.96 | $0.0M | Form 4 |
| Dec 8, 2025 | Kurt A GustafsonExecutive VP, Finance and CFO | Sold | 23,922 | $1.96 | $0.0M | Form 4 |
| Dec 8, 2025 | Matthew W FoehrPresident and CEO, Director | Sold | 13,666 | $1.96 | $0.0M | Form 4 |
| Nov 7, 2025 | John L HigginsDirector | Bought | 41,038 | $1.38 | $0.1M | Form 4 |
| Nov 6, 2025 | John L HigginsDirector | Bought | 36,223 | $1.41 | $0.1M | Form 4 |
Can it carry its debts, and how well does it use its money?
Cash, debt and the ratios that show how comfortably OmniAb, Inc. can carry it.
In plain words: What the company owns and what it owes. More cash than debt is a cushion for bad times; a lot of debt leaves less room when business slows down.
Cash vs debt (incl. leases)
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | $0.0M | $88.3M | $87.0M | $59.4M | $54.0M |
| Interest coverage | β5,087.0x | β | β | β | β |
| Current ratio | 1.1x | 4.8x | 4.1x | 4.5x | 4.0x |
| Quick ratio | 1.1x | 4.8x | 4.1x | 4.5x | 4.0x |
| Total assets | $304M | $421M | $375M | $326M | $301M |
| Total liabilities | $70.2M | $79.8M | $60.6M | $37.9M | $33.9M |
| Shareholders' equity | $234M | $341M | $315M | $288M | $267M |
| Net debt (β = net cash) | β | β | β | β | β |
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
In plain words: How much profit the business makes on the money put into it. A higher percentage means each dollar invested works harder.
Return on capital, equity and assets (annual)
KIRA Β· OmniAb, Inc. passes 1 of 7 financial health tests (Piotroski F-score).
Nine pass/fail tests of profitability, funding and efficiency. 8β9 is strong, 0β2 weak.
In plain words: Nine yes/no tests of financial health, one point each. A green tick is a pass: 7 to 9 points is solid, 0 to 3 is weak.
| Test | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Net income is positive | β | β | β | β | β |
| Cash from operations is positive | β | β | β | β | β |
| Return on assets rose | β | β | β | β | β |
| Cash from operations exceeds net income | β | β | β | β | β |
| Debt fell relative to assets | β | β | β | β | β |
| Current ratio rose | β | β | β | β | β |
| Share count didn't rise | β | β | β | β | β |
| Gross margin rose | β | β | β | β | β |
| Revenue rose relative to assets | β | β | β | β | β |
| F-score | β / 3 | 4 / 7 | 2 / 7 | 2 / 7 | 1 / 7 |
| Accruals ratio | β7.0% | β5.2% | β13.3% | β6.4% | β9.0% |
| Altman Z'' | 2.76 | 5.69 | 5.12 | 6.48 | 6.00 |
Every number, year by year.
Amounts in USD. Hover a ratioβs name for its definition.
In plain words: Every number we have, year by year. Download it as a spreadsheet if you want to dig deeper.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $34.7M | $59.1M | $34.2M | $26.4M | $18.7M |
| Research and development | $39.2M | $48.4M | $56.5M | $55.1M | $47.8M |
| Operating income | β$35.6M | β$26.6M | β$69.4M | β$74.5M | β$69.0M |
| Interest expense | $0.0M | $0.0M | β | β | β |
| Pretax income | β$34.4M | β$26.1M | β$64.4M | β$71.4M | β$66.3M |
| Income tax | β$7.3M | β$3.7M | β$13.7M | β$9.4M | β$1.5M |
| Net income | β$27.0M | β$22.3M | β$50.6M | β$62.0M | β$64.8M |
| Diluted EPS | β$0.33 | β$0.26 | β$0.51 | β$0.61 | β$0.57 |
| Diluted shares | 0.08B | 0.09B | 0.10B | 0.10B | 0.11B |
| Cash flow | |||||
| Cash from operations | β$5.7M | β$3.6M | $2.3M | β$39.7M | β$36.5M |
| Capital expenditure | $4.1M | $17.2M | $1.6M | $1.9M | $0.6M |
| Free cash flow | β$9.7M | β$20.8M | $0.7M | β$41.5M | β$37.0M |
| Depreciation and amortization | $16.3M | $18.2M | $19.5M | $23.6M | $21.8M |
| Stock-based compensation | $15.1M | $18.3M | $24.8M | $21.5M | $15.8M |
| Balance sheet | |||||
| Cash and short-term investments | $0.0M | $88.3M | $87.0M | $59.4M | $54.0M |
| Current assets | $22.5M | $125M | $94.9M | $68.1M | $65.3M |
| Current liabilities | $20.6M | $26.0M | $23.1M | $15.1M | $16.3M |
| Inventory | β | β | β | $0.0M | $0.8M |
| Property and equipment, net | $6.8M | $20.0M | $18.2M | $15.5M | $9.4M |
| Goodwill | $84.0M | $84.0M | $84.0M | $84.0M | $84.0M |
| Intangible assets | $176M | $167M | $155M | $138M | $125M |
| Total assets | $304M | $421M | $375M | $326M | $301M |
| Total liabilities | $70.2M | $79.8M | $60.6M | $37.9M | $33.9M |
| Preferred stock | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M |
| Shareholders' equity | $234M | $341M | $315M | $288M | $267M |
| Margins | |||||
| Operating margin | β102.5% | β45.1% | β203.2% | β282.3% | β369.5% |
| EBITDA margin | β55.7% | β14.2% | β146.1% | β192.9% | β252.9% |
| Net margin | β77.8% | β37.8% | β148.2% | β235.1% | β347.0% |
| FCF margin | β28.0% | β35.1% | 2.1% | β157.4% | β198.3% |
| Returns | |||||
| Return on capital employed | β12.5% | β6.7% | β19.7% | β24.0% | β24.2% |
| Return on equity | β11.5% | β7.8% | β15.4% | β20.6% | β23.4% |
| Return on assets | β8.9% | β6.2% | β12.7% | β17.7% | β20.7% |
| Return on tangible equity | β | β24.8% | β67.4% | β94.6% | β111.9% |
| Growth | |||||
| Revenue growth | β | 70.0% | β42.2% | β22.8% | β29.3% |
| FCF growth | β | β | β | β6,008.8% | β |
| Share count change | β | 3.3% | 16.8% | 2.7% | 11.0% |
| Financial health | |||||
| Interest coverage | β5,087.0x | β | β | β | β |
| Current ratio | 1.1x | 4.8x | 4.1x | 4.5x | 4.0x |
| Quick ratio | 1.1x | 4.8x | 4.1x | 4.5x | 4.0x |
| Capital allocation | |||||
| Capex / revenue | 11.7% | 29.1% | 4.8% | 7.1% | 3.0% |
| Stock comp / revenue | 43.4% | 31.0% | 72.6% | 81.5% | 84.8% |
| Quality scores | |||||
| Piotroski F-score | β | 4.0 | 2.0 | 2.0 | 1.0 |
| Altman Z'' | 2.8 | 5.7 | 5.1 | 6.5 | 6.0 |
| Accruals ratio | β7.0% | β5.2% | β13.3% | β6.4% | β9.0% |
Source: SEC EDGAR XBRL filings (CIK 0001846253). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only β not investment advice. Check the original filings before relying on any figure.
